by novabioticsadm1n | Aug 2, 2021 | 2021, Press Releases
Highlights proprietary peptide platform and immune-based approach with manifold therapeutic advantages over traditional drug classes to combat life-threatening fungal and bacterial infectious diseases Aberdeen, August 2, 2021. NovaBiotics Ltd, a privately held...
by Paul McIntosh | Jul 7, 2021 | 2021, Press Releases
NovaBiotics were highlighted in Jonathan Smith’s article in Labiotech on “Scotland’s Top Ten Biotech Companies to Watch Out For.” Learn more about Scotland’s “thriving life sciences ecosystem” by accessing the article Labiotech Article Scotland’s Top Ten...
by Paul McIntosh | Jun 21, 2021 | 2021, Press Releases
Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias Aberdeen, June 21, 2021. NovaBiotics Ltd, a privately held clinical stage company...
by Paul McIntosh | Jun 1, 2021 | 2021, Press Releases
Peer reviewed journal article highlights Company’s novel antifungal peptide’s activity against a broad range of fungal pathogens with no off target cytotoxicity Aberdeen, June 1, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune...
by Paul McIntosh | May 21, 2021 | 2021, Events
NovaBiotics are looking forward to participating at the upcoming BIO Digital Meeting taking place on June 10-11 & 14-18, 2021. The team are ready to meet with all interested parties and explain how we are using immunology to deliver novel therapies for...
Recent Comments